Emergent BioSolutions (EBS) Reports Q3 results; updates guidance
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.76 +3.21%
EPS Growth %: -138.7%
Financial Fact:
Product sales: 96.7M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -138.7%
Financial Fact:
Product sales: 96.7M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 Revenue for the quarter at $271 million versus the consensus estimate of $237.43 million.
GUIDANCE:
Emergent BioSolutions sees FY2023 revenue of $1-1.1 billion, versus the consensus of $1.04 billion.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KB Home (KBH) Tops Q3 EPS by 16c
- AnaptysBio, Inc. (ANAB) Tops Q2 EPS by 524c
- Bernstein SocGen Group Starts Amphenol (APH) at Outperform
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
